Working... Menu

The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02979587
Recruitment Status : Active, not recruiting
First Posted : December 1, 2016
Last Update Posted : April 16, 2019
Information provided by (Responsible Party):
Medtronic Cardiovascular ( Medtronic Heart Valves )

Brief Summary:
The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™ TPV system.

Condition or disease Intervention/treatment Phase
Congenital Heart Disease Tetrology of Fallot RVOT Anomaly Pulmonary Regurgitation Device: Harmony TPV System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study
Actual Study Start Date : January 2017
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : November 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Harmony TPV System
Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems
Device: Harmony TPV System
The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame. The Harmony™ TPV (Model HTPV254952) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22. The Harmony Delivery System for both the TPV 22 and TPV 25 (NTPVDS0022 and HTPVDS0025) are both 25 Fr coil loading catheter delivery systems.

Primary Outcome Measures :
  1. Freedom from procedure- or device-related mortality at 30 days. [ Time Frame: 30 days ]
  2. Percentage of subjects with acceptable hemodynamic function composite at 6 months. [ Time Frame: 6 months ]

    Defined as:

    • Mean RVOT gradient as measured by continuous‐wave Doppler ≤40 mmHg ‐AND‐
    • Pulmonary regurgitant fraction as measured by magnetic resonance imaging <20%

Secondary Outcome Measures :
  1. Technical success at exit from catheterization lab/operating room (OR) [ Time Frame: At exit from catheterization lab/operating room (OR) ]
  2. Device Success out to 5 years [ Time Frame: 5 years ]
  3. Procedural Success at 30 days [ Time Frame: 30 days ]
  4. Freedom from TPV Dysfunction out to 5 years [ Time Frame: 5 years ]
  5. Assessment of safety [ Time Frame: 5 years ]
    All procedure-related serious adverse events. All device-related serious adverse events. Death (all-cause, procedural, and device-related).

  6. Characterization of quality of life scores out to 5 years [ Time Frame: 5 years ]
    As assessed via the SF-36 QOL form.

  7. Characterization of right ventricle remodeling following TPV implant [ Time Frame: 5 years ]
    As assessed via cardiac magnetic resonance imaging

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has severe pulmonary regurgitation as assessed via echocardiography or CMR determined PR fraction >/= 30%
  • Subject has clinical indication for surgical placement of an RV-PA conduit or bioprosthetic pulmonary valve
  • Subject is willing to consent to participate

Exclusion Criteria:

  • Patients with right ventricular outflow tract obstruction (RVOTO) lesions surgically treated with an RV-to-PA conduit implant
  • RVOT anatomy or morphology that is unfavorable for device anchoring
  • Positive pregnancy test
  • Life expectancy of less than 1 year

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02979587

Layout table for location information
United States, California
Ronald Regan UCLA Medical Center
Los Angeles, California, United States, 90095
Stanford University Medical Center
Palo Alto, California, United States, 94304
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06510
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55902
United States, Ohio
Nationwide Children's Hospital
Columbus, Ohio, United States, 43215
United States, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Texas Children's Hospital
Houston, Texas, United States, 77030
United States, Utah
Primary Children's Hospital
Salt Lake City, Utah, United States, 84113
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Canada, Ontario
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada, M5G 1X8
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
National Cerebral and Cardiovascular Center
Suita, Osaka, Japan, 565-8565
Sakakibara Heart Institute
Fuchu, Tokyo, Japan, 183-0003
Sponsors and Collaborators
Medtronic Heart Valves
Layout table for investigator information
Principal Investigator: John P Cheatham, MD Nationwide Children's Hospital

Layout table for additonal information
Responsible Party: Medtronic Heart Valves Identifier: NCT02979587     History of Changes
Other Study ID Numbers: MDT16004CON001
First Posted: December 1, 2016    Key Record Dates
Last Update Posted: April 16, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Pulmonary Valve Insufficiency
Respiratory Insufficiency
Tetralogy of Fallot
Cardiovascular Diseases
Heart Valve Diseases
Respiration Disorders
Respiratory Tract Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Congenital Abnormalities